Nakamura K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial. Mult Scler 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
PMID: 38469809